A high-conviction bearish opportunity is identified in Inmune Bio (INMB), with a prediction that the stock could fall 90% following its upcoming clinical data release. This thesis is based on a recent financing deal where INMB sold shares at a massive discount, signaling management's lack of confidence in their own data. Conversely, Sarepta Therapeutics (SRPT) is presented as a major long-term investment holding due to its recovery potential, despite recent underperformance. Other stocks with a strong bearish outlook include Anavex (AVXL), Capricor (CAPR), and IonQ (IONQ), which are viewed as potential short-selling candidates. For investors seeking stability, Intercontinental Exchange (ICE) is highlighted as a high-quality company with a very profitable business model.

Inmune Bio (INMB)

• The speaker, Martin Shkreli, has an extremely bearish outlook on INMB and is actively shorting the stock. He predicts the stock will drop 90% following their upcoming data release.
• The primary red flag is a recent registered direct (RD) offering. The company sold shares to institutional investors at $6.30 per share while the stock was trading in the open market at around $14.
• Shkreli's thesis is that no company with positive upcoming clinical trial data would dilute shareholders at such a massive discount. They would wait for the good news, let the stock price rise, and then raise capital at a much higher valuation (e.g., $60 per share).
• He theorizes the financing was a "cleanest, nastiest arbitrage" trade. Hedge funds likely shorted the stock from its highs ($12-$14) and then covered their short positions with the shares they bought in the RD at $6.30, locking in a large, nearly risk-free profit.
• The company's willingness to accept this deal signals, in his view, that they are desperate for cash and know their upcoming Alzheimer's data is bad.
• He also criticizes the scientific basis for the company's drug, arguing that the link between their target (TNF-alpha) and Alzheimer's is based on flawed, non-causal statistical analysis and that other drugs targeting similar biological pathways have already failed.

Takeaways

• The core investment insight is that the company's financing decision is a strong signal of management's lack of confidence in their upcoming clinical trial data.
• This is presented as a high-conviction short-selling opportunity, based on the belief that the company is raising money out of desperation before an anticipated stock price collapse.
• Investors who are long the stock are warned that this action is a "betrayal" of retail investors and a sign of impending negative news.

Sarepta Therapeutics (SRPT)

• Shkreli states that SRPT is his biggest long position, making up 10% of his portfolio.
• Despite this, he expresses frustration with its recent performance, calling it a "gigantic piece of dog shit" and a "fucking dog."
• He clarified that he holds the position because he believes it can recover, not because he thinks it's "over." He did sell a small amount to free up capital for the INMB short.

Takeaways

• This is a long-term, high-conviction investment for the speaker, despite his vocal frustration with its short-term price action.
• The insight for investors is that even experienced managers hold positions through periods of underperformance if their long-term thesis remains intact.

Other Biotech & Tech Mentions

• Cassava Sciences (SAVA): Mentioned as a past successful short. Shkreli refers to it as a "fraud from the start" and a company on which he "made millions" by shorting. This is used to establish his track record in identifying flawed biotech companies.
• Anavex Life Sciences (AVXL): Identified as a future short target that is "coming soon." He describes it as "largely a scam."
• Capricor Therapeutics (CAPR): Mentioned in a list of biotech stocks that are "next" and "all going to zero." This is a strong bearish call.
• IonQ (IONQ): Shkreli confirms he is still short this stock.
• Biotech Sector ETF (XBI): He points to the XBI chart as evidence that the biopharma sector has been "dead" for 15 years, suggesting that broad, passive investment in the sector is a poor strategy.

Takeaways

• Shkreli has a list of biotech companies he is actively shorting or plans to short, including AVXL, CAPR, and IONQ, based on his belief that they are fundamentally flawed.
• He advises against broad investment in the biotech sector, favoring a highly selective, stock-picker's approach due to the sector's overall poor performance.

Private & Public Market Opportunities

• OpenAI (Private): Shkreli is extremely bullish on OpenAI, stating it is "going to 10 trillion." He notes that shares of large private companies like OpenAI, SpaceX, and Stripe trade daily in private markets.
• Intercontinental Exchange (ICE): He briefly analyzed ICE, the owner of the New York Stock Exchange, and was very impressed by its business model.
  • He highlighted its extremely high operating margin of 66%.
  • He noted that its largest revenue segments are energy exchanges and data services, not just stock exchange listings.

Takeaways

• For accredited investors, there may be opportunities in trading shares of large, late-stage private companies like OpenAI before they go public.
• ICE is highlighted as a high-quality, mature company with a very profitable, high-margin business model, which could be attractive to investors looking for stable, cash-generating businesses.

General Market Commentary

• Shkreli expressed a bearish view on passive investing in the S&P 500 for the average person.
• He argues that after accounting for inflation and taxes, the real returns are very low (around 2%).
• He describes the market as a "rigged game" where large, sophisticated hedge funds (Citadel, Jane Street, Millennium) have a massive advantage over retail investors.

Takeaways

• The speaker believes that successful investing requires a full-time dedication and deep expertise.
• He cautions the general public against casually participating in the stock market, suggesting that the odds are stacked against them and that passive index fund returns may be less attractive than they appear once inflation and taxes are considered.